130 related articles for article (PubMed ID: 12472096)
1. Severe ulcers on celecoxib.
Prescrire Int; 2002 Dec; 11(62):182-3. PubMed ID: 12472096
[No Abstract] [Full Text] [Related]
2. Celecoxib for rheumatoid arthritis.
Megeff CE; Strayer SM
J Fam Pract; 2000 Feb; 49(2):108-9. PubMed ID: 10718683
[No Abstract] [Full Text] [Related]
3. Celecoxib and the CLASS trial: data massaging by industry.
Prescrire Int; 2002 Dec; 11(62):190-1. PubMed ID: 12472103
[No Abstract] [Full Text] [Related]
4. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
[No Abstract] [Full Text] [Related]
5. [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and "cost effectiveness"].
Kellner H
Krankenpfl J; 2004; 42(5-6):185. PubMed ID: 15527245
[No Abstract] [Full Text] [Related]
6. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Blondon H
Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
[No Abstract] [Full Text] [Related]
7. Balancing the risks and benefits of celecoxib.
Caldwell B; Beasley R; Weatherall M; Metcalfe S
Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
[No Abstract] [Full Text] [Related]
8. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
[No Abstract] [Full Text] [Related]
9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
10. [Celecoxib and the CLASS study--worse and worse...].
Slørdal L
Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2219. PubMed ID: 12426903
[No Abstract] [Full Text] [Related]
11. Allergic vasculitis associated with celecoxib.
Jordan KM; Edwards CJ; Arden NK
Rheumatology (Oxford); 2002 Dec; 41(12):1453-5. PubMed ID: 12468830
[No Abstract] [Full Text] [Related]
12. Nonsteroidal anti-inflammatory drugs, cyclooxygenase inhibitors, and the risk of gastrointestinal complications.
Cheskin LJ
Am J Manag Care; 2001 Sep; 7(12 Suppl):S395-6. PubMed ID: 11570030
[No Abstract] [Full Text] [Related]
13. [Therapy with COX-2 inhibitors. Less risk--better tolerance].
MMW Fortschr Med; 2000 Dec; 142(49-50):65-6. PubMed ID: 11190944
[No Abstract] [Full Text] [Related]
14. Valdecoxib (Bextra)--a new cox-2 inhibitor.
Med Lett Drugs Ther; 2002 Apr; 44(1129):39-40. PubMed ID: 11981510
[No Abstract] [Full Text] [Related]
15. [Celecoxib and the CLASS study--a statement].
Wibe E; Maehlum S
Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2218. PubMed ID: 12426902
[No Abstract] [Full Text] [Related]
16. [Celecoxib].
Fux R; Mörike K; Gleiter CH
Dtsch Med Wochenschr; 2002 Apr; 127(15):803-4. PubMed ID: 11951138
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis.
Suárez-Otero R; Robles-San Román M; Jaimes-Hernández J; Oropeza-De La Madrid E; Medina-Peñaloza RM; Rosas-Ramos R; Castañeda-Hernández G
Proc West Pharmacol Soc; 2002; 45():26-8. PubMed ID: 12434517
[No Abstract] [Full Text] [Related]
18. [Gastroduodenal tolerance of celecoxib (celebrex) in patients with osteoarthrosis: an endoscopic evaluation].
Karateev AE
Ter Arkh; 2001; 73(5):63-4. PubMed ID: 11517755
[No Abstract] [Full Text] [Related]
19. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Geis GS
BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
[No Abstract] [Full Text] [Related]
20. [Celecoxib and the CLASS trial].
Englev E; Christensen KB
Ugeskr Laeger; 2002 Oct; 164(41):4825-6. PubMed ID: 12407895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
